Leap Therapeutics held its 2023 Annual Meeting of Stockholders on June 16, 2023, where various matters were voted on and approved, including the election of directors, executive compensation, future advisory votes on executive compensation, amendment to the equity incentive plan, appointment of independent registered public accounting firm, issuance of common stock upon conversion of preferred stock, and amendment to the certificate of incorporation for a reverse stock split. The conversion of Series X Preferred Stock occurred on June 21, 2023, resulting in 24,005,499 shares of common stock issued and outstanding.